The company had previously adjusted its Q1 revenue guidance from the end of 2015 downward on lower-than-expected adoption of the test during the quarter.
The company also cut its Q1 revenue guidance after a lower-than-expected number of customers adopting its sepsis test during the quarter.
The company's net loss increased on higher expenses associated with an expanded sales force for its Candida tests, as well as ongoing development of new tests.
Executives from Luminex, Exact Sciences, T2 Biosystems, and Singulex provided updates on their companies' businesses on the final day of the conference.
Foundation Medicine, Natera, and Genomic Health also showed double-digit percentage increases in December.
The firm has closed its public offering but underwriters could buy an additional 525,000 shares and the firm has filed to sell up to $100 million in stock.
The company said that it would offer 3.5 million shares of its common stock at $9.75 a share, giving the sale a value of $34.1 million before costs.
The company said it plans to offer the underwriters of the offering an option to buy an additional 525,000 shares of its stock at the public offering price.
The company said that it had contracts for its Candida test and related T2Dx instrumentation with 19 hospitals at the end of the third quarter.
The test is being positioned alongside the recently approved fungal infection panel T2Candida for the diagnosis of most sepsis-causing infections.
Researchers uncovered the HIV virus within a tissue sample collected in 1966, the Atlantic reports.
Nature News reports there are a handful of clinical trials underway to evaluate vaginal microbiome seeding of newborns born via caesarian section.
The Washington Post writes that humans may have contributed to the extinction of cave bears some 20,000 years ago.
In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.